FI3866931T3 - Deuteriumia sisältäviä yhdisteitä - Google Patents
Deuteriumia sisältäviä yhdisteitä Download PDFInfo
- Publication number
- FI3866931T3 FI3866931T3 FIEP19790194.5T FI19790194T FI3866931T3 FI 3866931 T3 FI3866931 T3 FI 3866931T3 FI 19790194 T FI19790194 T FI 19790194T FI 3866931 T3 FI3866931 T3 FI 3866931T3
- Authority
- FI
- Finland
- Prior art keywords
- mol
- deuterium
- compound according
- compound
- abundance level
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 title claims 15
- 229910052805 deuterium Inorganic materials 0.000 title claims 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816998.7A GB201816998D0 (en) | 2018-10-18 | 2018-10-18 | Compounds |
| GBGB1909695.7A GB201909695D0 (en) | 2019-07-05 | 2019-07-05 | Compounds |
| PCT/EP2019/078250 WO2020079165A1 (en) | 2018-10-18 | 2019-10-17 | Compounds containing deuterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3866931T3 true FI3866931T3 (fi) | 2023-05-10 |
Family
ID=68290247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19790194.5T FI3866931T3 (fi) | 2018-10-18 | 2019-10-17 | Deuteriumia sisältäviä yhdisteitä |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12152087B2 (enExample) |
| EP (1) | EP3866931B1 (enExample) |
| JP (2) | JP7603199B2 (enExample) |
| KR (1) | KR102848971B1 (enExample) |
| CN (1) | CN112930214B (enExample) |
| AU (1) | AU2019362389B2 (enExample) |
| BR (1) | BR112021007060A2 (enExample) |
| CA (1) | CA3116198A1 (enExample) |
| DK (1) | DK3866931T3 (enExample) |
| ES (1) | ES2942468T3 (enExample) |
| FI (1) | FI3866931T3 (enExample) |
| HU (1) | HUE061801T2 (enExample) |
| IL (1) | IL282231B2 (enExample) |
| MA (1) | MA53904A (enExample) |
| MX (1) | MX2021004474A (enExample) |
| PL (1) | PL3866931T3 (enExample) |
| SG (1) | SG11202103726RA (enExample) |
| WO (1) | WO2020079165A1 (enExample) |
| ZA (1) | ZA202102492B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| EP4347615B1 (en) * | 2021-06-01 | 2025-05-21 | Synthon B.V. | Process for making melflufen or a salt thereof |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| US20240307480A1 (en) | 2021-07-08 | 2024-09-19 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
| WO2026057823A1 (en) * | 2024-09-13 | 2026-03-19 | Oncopeptides Ab | Bis-chloroethylamino derivatives for treating leukemia |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| NZ591615A (en) | 2008-09-18 | 2012-07-27 | Auspex Pharmaceuticals Inc | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20120003330A1 (en) | 2010-06-01 | 2012-01-05 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| SI3228319T1 (sl) | 2011-04-28 | 2020-10-30 | Oncopeptides Ab | Liofiliziran pripravek citotoksičnih dipeptidov |
| JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| JP6284945B2 (ja) * | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
| EA202091397A1 (ru) | 2013-01-31 | 2020-09-04 | Ауспекс Фармацетикалс, Инк. | Бензохинолоновые ингибиторы vmat2 |
| JP6704252B2 (ja) | 2013-02-05 | 2020-06-03 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬 |
| AU2014357518A1 (en) | 2013-12-03 | 2016-06-09 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| CN104725380B (zh) * | 2013-12-18 | 2019-06-28 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| PL3265085T3 (pl) | 2015-03-06 | 2022-11-07 | Auspex Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
-
2019
- 2019-10-17 WO PCT/EP2019/078250 patent/WO2020079165A1/en not_active Ceased
- 2019-10-17 CA CA3116198A patent/CA3116198A1/en active Pending
- 2019-10-17 SG SG11202103726RA patent/SG11202103726RA/en unknown
- 2019-10-17 KR KR1020217011490A patent/KR102848971B1/ko active Active
- 2019-10-17 EP EP19790194.5A patent/EP3866931B1/en active Active
- 2019-10-17 MX MX2021004474A patent/MX2021004474A/es unknown
- 2019-10-17 FI FIEP19790194.5T patent/FI3866931T3/fi active
- 2019-10-17 MA MA053904A patent/MA53904A/fr unknown
- 2019-10-17 AU AU2019362389A patent/AU2019362389B2/en active Active
- 2019-10-17 BR BR112021007060-5A patent/BR112021007060A2/pt unknown
- 2019-10-17 DK DK19790194.5T patent/DK3866931T3/da active
- 2019-10-17 ES ES19790194T patent/ES2942468T3/es active Active
- 2019-10-17 IL IL282231A patent/IL282231B2/en unknown
- 2019-10-17 HU HUE19790194A patent/HUE061801T2/hu unknown
- 2019-10-17 JP JP2021521145A patent/JP7603199B2/ja active Active
- 2019-10-17 CN CN201980068384.1A patent/CN112930214B/zh active Active
- 2019-10-17 PL PL19790194.5T patent/PL3866931T3/pl unknown
- 2019-10-17 US US17/286,002 patent/US12152087B2/en active Active
-
2021
- 2021-04-15 ZA ZA2021/02492A patent/ZA202102492B/en unknown
-
2024
- 2024-07-03 JP JP2024107578A patent/JP2024150488A/ja active Pending
- 2024-10-16 US US18/917,773 patent/US20250115637A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2942468T3 (es) | 2023-06-01 |
| MA53904A (fr) | 2021-08-25 |
| US12152087B2 (en) | 2024-11-26 |
| SG11202103726RA (en) | 2021-05-28 |
| CN112930214B (zh) | 2025-05-16 |
| US20250115637A1 (en) | 2025-04-10 |
| AU2019362389A1 (en) | 2021-06-03 |
| JP2024150488A (ja) | 2024-10-23 |
| JP2022512736A (ja) | 2022-02-07 |
| CA3116198A1 (en) | 2020-04-23 |
| MX2021004474A (es) | 2021-08-24 |
| KR20210078487A (ko) | 2021-06-28 |
| BR112021007060A2 (pt) | 2021-07-20 |
| IL282231B2 (en) | 2025-07-01 |
| WO2020079165A1 (en) | 2020-04-23 |
| US20210388024A1 (en) | 2021-12-16 |
| IL282231A (en) | 2021-05-31 |
| IL282231B1 (en) | 2025-03-01 |
| AU2019362389B2 (en) | 2024-12-12 |
| HUE061801T2 (hu) | 2023-08-28 |
| EP3866931B1 (en) | 2023-02-15 |
| CN112930214A (zh) | 2021-06-08 |
| DK3866931T3 (da) | 2023-04-24 |
| ZA202102492B (en) | 2024-04-24 |
| KR102848971B1 (ko) | 2025-08-21 |
| PL3866931T3 (pl) | 2023-06-19 |
| EP3866931A1 (en) | 2021-08-25 |
| JP7603199B2 (ja) | 2024-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241590T1 (hr) | Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba | |
| HRP20150744T4 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| CY1109457T1 (el) | Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει | |
| DE60010076D1 (de) | Chinolinderivate als antibakterielle mittel | |
| EA200701902A1 (ru) | Бициклические [3.1.0] гетероариламиды в качестве ингибиторов переноса глицина типа i | |
| MY139302A (en) | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
| EA200600892A1 (ru) | Новые хинолиновые производные | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| PH12012501881A1 (en) | 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication | |
| MY209034A (en) | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors | |
| HRP20150531T1 (hr) | Pirazolilaminopiridini kao inhibitori fak | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| MX345544B (es) | Derivados de triazol como ligandos para receptores de acido gamma-aminobutirico (gaba). | |
| JP2022512736A5 (enExample) | ||
| MX2007004740A (es) | Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica. | |
| MX2008012093A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos. | |
| GEP20115222B (en) | New pharmaceutical compounds | |
| PL367340A1 (en) | Quinoline derivatives and use thereof as antitumor agents |